期刊
CLINICAL NUCLEAR MEDICINE
卷 40, 期 8, 页码 621-626出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000000830
关键词
-
资金
- Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]
- China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project [BM104010092]
- NRPB Stroke Clinical Trial Consortium [MOST 103-2325-B-039 -006]
- Tseng-Lien Lin Foundation, Taichung, Taiwan
- Taiwan Brain Disease Foundation, Taipei, Taiwan
- Katsuzo and Kiyo Aoshima Memorial Funds, Japan
- China Medical University Hospital Cancer Research Center of Excellence (Taiwan) [MOHW104-TDU-B-212-124-002]
Purpose The aim of this study was to understand the association between various genetic mutation and F-18-FDG PET-related parameters in patients with colorectal cancer (CRC). Methods One hundred three CRC patients who had undergone preoperative PET/CTs were included in this study. Several PET/CT-related parameters, including SUVmax, and various thresholds of metabolic tumor volume, total lesion glycolysis, and PET/CT-based tumor width (TW) were measured. Using high-resolution melting methods for genetic mutation analysis, tumor- and PET/CT-related parameters were correlated with various genetic alterations including TP53, KRAS, APC, BRAF, and PIK3CA. Mann-Whitney U test and logistic regression analysis were carried out for this analysis. Results Genetic alterations in TP53, KRAS, and APC were found in 41 (40%), 34 (33%), and 27 (26%) of tumors, respectively. PIK3CA and BRAF were exhibited by 5 and 4 of the patients with CRC. TP53 mutants exhibited higher SUVmax. The odds ratio was 1.28 (P = 0.04; 95% confidence interval, 1.01-1.61). Tumors with a mutated KRAS had an increased accumulation of FDG using a 40% threshold level for maximal uptake of TW (TW40%), whereas the odds ratio was 1.15 (P = 0.001; 95% confidence interval, 1.06-1.24). The accuracy of SUVmax greater than 10 in predicting TP53 mutation was 60%, whereas that for TW40% for KRAS was 61%. Conclusions Increased SUVmax and TW40% were associated in CRC tumors with TP53 and KRAS mutations, respectively. Further studies are required because of the low predictive accuracy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据